Pommer v. Medtest Corp., 961 F.2d 620 (7th Cir. 1992)
Pommer v. Medtest Corp.
Whether a medical diagnostics company's forward-looking statements and opinions concerning expected FDA approval and commercial prospects, along with alleged omissions about interim setbacks, constitute actionable misrepresentations or omissions under Section 10(b) and Rule 10b-5 when plaintiffs cannot show the statements were false when made, lacked a reasonable basis, or were issued with scienter.
To establish liability under Section 10(b) and Rule 10b-5, a private plaintiff must prove: (1) a material misrepresentation or omission; (2) scienter (an intent to deceive, manipulate, or defraud, or at least recklessness in some circuits, including the Seventh); (3) a connection with the purchase or sale of a security; (4) reliance (transaction causation); (5) economic loss; and (6) loss causation. Statements of opinion, belief, or prediction are actionable only if (a) they misstate then-existing objective facts, (b) the speaker does not genuinely hold the opinion, or (c) the opinion or projection lacks a reasonable basis when made. Forward-looking statements that are couched in cautionary language and fairly disclose the underlying risks are generally not material misrepresentations under the bespeaks-caution doctrine. There is no freestanding duty to disclose every interim development; the duty is to avoid making statements that are materially misleading in light of the information then available. Subsequent nonoccurrence of a predicted event does not, by itself, establish falsity or scienter.
The Seventh Circuit affirmed judgment for Medtest, holding that the company's forward-looking and opinion statements regarding anticipated FDA approval and business prospects were not actionable under Rule 10b-5 where the plaintiff failed to show that the statements were false when made, lacked a reasonable basis, or were issued with scienter. The court also rejected liability premised on omissions of interim regulatory developments, concluding that Medtest had no duty to disclose every step of an uncertain process and that the company's use of cautionary language and disclosure of risks defeated claims of material misrepresentation.
Pommer v. Medtest is a staple for understanding how courts cabin Rule 10b-5 liability for projections and opinions. It teaches that disappointment ex post is not deception ex ante; falsity and scienter hinge on what the speaker knew and reasonably believed at the time. The decision synthesizes key limits on securities fraud, including the bespeaks-caution doctrine, the distinction between a duty to correct and a duty to update, and the non-actionability of vague corporate optimism. For law students, the case is a roadmap to analyzing forward-looking statements: identify the statement type (fact vs. opinion), test for falsity when made, probe for reasonable basis and genuine belief, evaluate cautionary context, and tie any alleged misstatement to materiality, reliance, and loss causation.